The spectrum of focal segmental glomerulosclerosis: New insights

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 3, 2008, Pages 271-281

  D'Agati, Vivette D ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Collapsing glomerulopathy; Focal segmental glomerulosclerosis; Podocyte; Proteinuria

Indexed keywords

ACTIN FILAMENT; APICAL MEMBRANE; CELL DIFFERENTIATION; CELL DISRUPTION; CLINICAL FEATURE; DISEASE MODEL; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS EPITHELIUM; HUMAN; KIDNEY INJURY; MINIMAL CHANGE GLOMERULONEPHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL DEDIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; GLOMERULAR BASEMENT MEMBRANE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MICROFILAMENTS; PHENOTYPE; PODOCYTES; SIGNAL TRANSDUCTION;

EID: 42149106794     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f94a96     Document Type: Review

References (103)

1. Habib R. Focal glomerulosclerosis. Kidney Int 1973; 4:355-361.
2. Rich AR. A hitherto undescribed vulnerability of the juxta-medullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 1957; 100:173-186.
3. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:117-134.
4. Schwartz MM, Korbet SM, Rydell J, et al. Primary focal segmental glomerular sclerosis in adults: prognostic value of histologic variants. Am J Kidney Dis 1995; 25:845-852.
5. D'Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int 1994; 46:1223-1241.
6. Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69:920-926.
7. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43:368-382.
8. D'Agati V, Suh J-I, Carbone L, Appel GB. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int 1989; 35:1358-1370.
9. Moudgil A, Nast CC, Bagga A, et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001; 59:2126-2133.
10. Li R-M, Branton MH, Tanawattanacharoen S, et al. Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 2002; 13:2320-2330.
11. Tomlinson L, Boriskin Y, McPhee I, et al. Acute cytomegalovirus infection complicated by collapsing glomerulopathy. Nephrol Dial Transplant 2003; 18:187-189.
12. Thaunat O, Delahousse M, Fakhouri F, et al. Nephrotic syndrome associated with hemophagocytic syndrome. Kidney Int 2006; 69:1892-1898.
13. Shah M, Jenis EH, Mookerjee BK, et al. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high-dose chemotherapy. Cancer 1998; 83:1938-1946.
14. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12:1164-1172.
15. Greenberg A, Bastacky SI, Iqbal A, et al. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. Am J Kidney Dis 1997; 29:334-344.
16. Thadhani R, Pascual M, Nickeleit V, et al. Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease. Lancet 1996; 347:231-233.
17. Avila-Casado MC, Vargas-Alarcon G, Soto ME, et al. Familial collapsing glomerulopathy: clinical, pathological and immunogenetic features. Kidney Int 2003; 63:233-239.
18. Nadasdy T, Allen C, Aand MS. Zonal distribution of glomerular collapse in renal allografts: possible role of vascular changes. Hum Pathol 2002; 33:437-441.
19. Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis 1999; 33:658-666.
20. Detwiler RK, Falk RJ, Hogan SL, Jennette JC. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994; 45:1416-1424.
21. Valeri A, Barisoni L, Appel GB, D'Agati V. Idiopathic collapsing focal segmental glomerulosclerosis: a clinico-pathologic study. Kidney Int 1996; 50:1734-1746.
22. Bariety J, Nochy D, Mandet C, et al. Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998; 53:918-928.
23. Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203-2213.
24. Singh HK, Baldree LA, McKenney DW, et al. Idiopathic collapsing glomeulopathy in children. Pediatr Nephrol 2000; 14:132-137.
25. Stokes MB, Markowitz GS, Lin J, et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65:1690-1702.
26. Howie AJ, Brewer DB. The glomerular tip lesion: a previously undescribed type of segmental glomerular abnormality. J Pathol 1984; 142:205-220.
27. Howie AJ, Pankhurst T, Sarioglu S, et al. Evolution of nephrotic-associated FSGS and relation to the glomerular tip lesion. Kidney Int 2005; 67:987-1001.
28. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59:1498-1509.
29. Harvey JM, Howie AJ, Lee SJ, et al. Renal biopsy findings in hypertensive patients with proteinuria. Lancet 1992; 340:1435-1436.
30. Falk RJ, Scheinman J, Phillips G, et al. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 1992; 326:910-915.
31. Rennke H, Klein PS. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis 1989; 13:443-455.
32. Stokes MB, Valeri AM, Markowitz GS, D'Agati VD. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int 2006; 70:1783-1792. This is the first study to characterize the clinical and pathologic features of the cellular variant of FSGS. It describes a prognosis that is intermediate between the tip and collapsing variants.
33. Deegens JK, Steenbergen EJ, Borm GF, Wetzels JF. Pathologic variants of focal segmental glomerulosclerosis in an adult Dutch population - epidemiology and outcome. Nephrol Dial Transplant 2008; 23:186-192.
34. Silverstein DM, Craver R. Presenting features and short-term outcome according to pathologic variant in childhood primary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:700-707.
35. Benzing T. Signaling at the slit diaphragm. J Am Soc Nephrol 2004; 15:1382-1391.
36. Marshall CB, Shankland SJ. Cell cycle regulatory proteins in podocyte health and disease. Nephron Exp Nephrol 2007; 106:E51-E59.
37. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54:687-697.
38. Bariety J, Bruneval P, Hill G, et al. Posttransplantation relapse of FSGS is characterized by glomerular epithelial cell transdifferentiation. J Am Soc Nephrol 2001; 12:261-274.
39. Kanno K, Kawachi H, Uchida Y, et al. Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract 2003; 95:91-99.
40. Petermann A, Floege J. Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 2007; 106:c61-c66.
41. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16:2941-2952.
42. Matsusaka T, Xin J, Niwa S, et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte specific injury. J Am Soc Nephrol 2005; 16:1013-1023.
43. Asano T, Niimura F, Pastan I, et al. Permanent genetic tagging of podocytes: fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol 2005; 16:2257-2262.
44. Ichikawa I, Ma J, Motojima M, Matsusaka T. Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens 2005; 14:205-210.
45. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992; 42:148-160.
46. Friedrich C, Endlich N, Kriz W, Endlich K. Podocytes are sensitive to fluid shear stress in vitro. Am J Physiol Renal Physiol 2006; 291:F856-F865.
47. Howie AJ, Ferreira MA, Majumdar A, Lipkin GW. Glomerular prolapse as precursor of one type of segmental sclerosing lesions. J Pathol 2000; 190:478-483.
48. Howie AJ. Changes at the glomerular tip: a feature of membranous nephropathy and other disorders associated with proteinuria. J Pathol 1986; 150:13-20.
49. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype; a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10:51-61.
50. Shankland SJ, Eitner F, Hudkins KL, et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000; 58:674-683.
51. Dijkman HB, Smeets B, van der Laak J, et al. The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int 2005; 68:1562-1572.
52. Dijkman HB, Weening JJ, Smeets B, et al. Proliferating cells in HIV and pamidronate associated collapsing FSGS are parietal epithelial cells. Kidney Int 2006; 70:338-344.
53. Smeets B, Dijkman HB, Wetzels JF, Steenbergen EJ. Lessons from studies on focal segmental glomerulosclerosis: an important role for parietal epithelial cells? J Pathol 2006; 210:263-272.
54. Bariety J, Mandet C, Hill GS, Bruneval P. Parietal podocytes in human glomeruli. J Am Soc Nephrol 2006; 17:2770-2780. This study used podocyte and parietal cell markers to demonstrate the existence of parietal podocytes lining a substantial portion of Bowman's capsule in the perihilar region. The existence of this population has implications for the origin of proliferating epithelial cells in collapsing FSGS.
55. Sagrinati C, Netti GS, Mazzinghi B, et al. Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006; 17:2443-2456.
56. Becker JU, Hoerning A, Schmid KW, Hoyer PF. Immigrating progenitor cells contribute to human podocyte turnover. Kidney Int 2007; 72:1468-1473. This study demonstrates that a small portion of the podocytes in the allograft may derive from stem cells, suggesting a mechanism of podocyte replenishment in health and disease.
57. •], this study shows the capacity for regeneration of podocytes through repopulation by stem cells leading to amelioration of pathologic features in a mouse model of Alport disease.
58. •], this shows the capacity for regeneration of podocytes through repopulation by stem cells leading to improvement in pathologic features in a mouse model of Alport disease.
59. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111:707-716.
60. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF - a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007; 106:32-37.
61. Neal CR, Crook H, Bell E, et al. Three-dimensional reconstruction of glomeruli by electron microscopy reveals a distinct restrictive urinary subpodocyte space. J Am Soc Nephrol 2005; 16:1223-1235.
62. Yap HK, Cheung W, Murugasu B, et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999; 10:529-537.
63. Lai K-W, Wei C-L, Tan L-K, et al. Overexpression of interleukin-13 induces minimal change-like nephropathy in rats. J Am Soc Nephrol 2007; 18:1476-1485. This study supports the cytokine theory of minimal change disease by demonstrating the ability of a specific interleukin to promote foot process effacement and nephrotic syndrome in association with upregulation of podocyte B7-1.
64. Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113:1390-1397.
65. Dijkman HB, Wetzels JF, Gemmink JH, et al. Glomerular involution in children with frequently relapsing minimal change nephrotic syndrome: an unrecognized form of glomerulosclerosis? Kidney Int 2007; 71:44-52. This study makes the intriguing observation that glomerular involution is more common in childhood relapsing minimal change disease than previously recognized and may be an important cause of nephron depletion in early childhood.
66. Ma J, Rossini M, Yang H-C, et al. Effects of podocyte injury on glomerular development. Pediatr Res 2007; 62:417-421. Using a model of puromycin aminonucleoside nephrosis, the investigators demonstrate that immature glomeruli exposed to podocyte toxins may undergo involution through a process of altered podocyte-endothelial signaling.
67. Schumacher VA, Jeruschke S, Eitner F, et al. Impaired glomerular maturation and lack of VEGF165b on Denys Drash syndrome. J Am Soc Nephrol 2007; 18:719-729. This study emphasizes the important role of VEGF signaling in glomerular maturation. It shows that impairment in this signaling axis may promote the phenotype of diffuse mesangial sclerosis.
68. Verma R, Kovari I, Soofi A, et al. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 2006; 116:1346-1359.
69. Jones N, Blasutig IM, Eremina V, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature 2006; 440:818-823. This study shows that Nck adaptor proteins are essential to link nephrin to actin and show that a podocyte-specific conditional knockout of Nck1 and Nck2 develops FSGS.
70. Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24:251-256.
71. Kos CH, Le TC, Sinha S, et al. Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest 2003; 111:1683-1690.
72. Danapani SV, Sugimoto H, Matthews BD, et al. α-Actinin-4 is required for normal podocyte adhesion. J Biol Chem 2007; 282:467-477. This study demonstrates that mutations in α-actinin-4 lead to podocyte depletion through a defect in podocyte adhesion to extracellular matrix.
73. Weins A, Schlondorff JS, Nakamura F, et al. Disease-associated mutant α-actinin-4 reveals a mechanism for regulating its F-actin-binding affinity. Proc Natl Acad Sci USA 2007; 104:16080-16085. This shows how a specific point mutation in α-actinin-4 can promote actin aggregation by increased binding affinity and escape from calcium regulation.
74. Michaud J-LR, Chaisson KM, Parks RJ, Kennedy CR. FSGS-associated α-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int 2006; 70:1054-1061.
75. Sever S, Altintas MM, Nankoe SR, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism of proteinuric kidney disease. J Clin Invest 2007; 117:2095-2104. This describes a novel mechanism of foot process effacement and proteinuria mediated by podocyte induction of a lysosomal enzyme that cleaves a specific actin-associated protein.
76. Eyre J, Ioannou K, Grubb BD, et al. Statin-sensitive endocytosis of albumin by glomerular podocytes. Am J Physiol Renal Physiol 2007; 292:F674-F681. This study demonstrates the ability of podocytes in vitro to endocytose albumin and underscores the potential for protein trafficking through the podocyte as a potential pathogenetic mediator.
77. Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38:1397-1404. Mutation of a specific phospholipase C enzyme located in the podocyte cell body and intermediate processes has been identified as a new genetic basis for familial FSGS or DMS.
78. Chaib J, Hoskins BE, Ashraf S, et al. Identification of BRAF as a new interactor of PLCε1, the protein mutation in nephrotic syndrome type 3. Am J Physiol Renal Physiol 2008; 294:F93-F99.
79. Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1:575-582.
80. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24:349-354.
81. Kim JM, Wu H, Green G, et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003; 300:1298-1300.
82. Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308:1801-1804.
83. Asanuma K, Campbell KN, Kim K, et al. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc Natl Acad Sci USA 2007; 104:10134-10139. Dendrin is a novel slit diaphragm protein. Upon podocyte injury, it dissociates from a complex with nephrin and relocates to the nucleus, where it promotes apoptotic signaling.
84. Nakajo A, Khoshnoodi J, Takenaka H, et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol 2007; 18:2554-2564. This study explores the concept of ER stress as a cause for podocyte dysfunction through failure of posttranslational processing and membrane targeting of critical proteins such as nephrin.
85. Gelberg H, Healy L, Whiteley H, et al. In vivo enzymatic removal of alpha 2-6 linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury. Lab Invest 1996; 74:907-920.
86. Seiler MW, Rennke HG, Venkatachalam MA, Cotran RS. Pathogenesis of polycation-induced alterations ('fusion') of glomerular epithelium. Lab Invest 1977; 36:48-61.
87. Galeano B, Klootwijk R, Manoli I, et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest 2007; 117:1585-1594. This study provides the first genetic model of foot process effacement and proteinuria mediated by defective sialation of podocalyxin.
88. Kaufman L, Yang G, Hayashi K, et al. The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy. FASEB J 2007; 21:1367-1375. This study identifies a novel podocyte adhesion molecule as a mediator of podocyte clustering and pseudocrescent formation in collapsing FSGS.
89. Kaufman L, Hayashi K, Ross MJ, et al. Sidekick-1 is up-regulated in glomeruli in HIV-associated nephropathy. J Am Soc Nephrol 2004; 15:1721-1730.
90. Yamagata M, Weiner JA, Sanes JR. Sidekicks: synaptic adhesion molecules that promote lamina-aspecific connectivity in the retina. Cell 2002; 110:649-660.
91. Karamatic Crew VN, Burton A, Kagan CA, et al. CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin. Blood 2004; 104:2217-2223.
92. Sachs N, Kreft M, van den Bergh Weerman MA, et al. Kidney failure in mice lacking the tetraspanin CD151. J Cell Biol 2006; 175:33-39. A member of the tetraspanin family of adhesion proteins, CD151, is expressed in podocytes. This study demonstrates that CD151 null mice develop proteinuria and FSGS.
93. Dai C, Stolz DB, Bastacky SI, et al. Essential role of integrin-linked kinase in podocyte biology: bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol 2006; 17:2164-2175. This study illustrates that integrin-linked kinase is essential for podocyte function. Podocyte-specific ablation of this protein leads to proteinuria and FSGS in a murine model.
94. Lin W, Burgess RW, Dominguez B, et al. Distinct roles of nerve and muscle postsynaptic differentiation of the neuromuscular synapse. Nature 2001; 410:1057-1064.
95. Harvey SJ, Jarad G, Cunningham J, et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171:139-152.
96. Zenker M, Aigner T, Wendler O, et al. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 2004; 13:967-975.
97. Jarad G, Cunningham J, Shaw AS, Miner JH. Proteinuria precedes podocyte abnormalities in Lamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 2006; 116:2272-2279.
98. Logar CM, Brinkkhoetter PT, Krofft RD, et al. Darbepoietin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72:489-498. This study demonstrates that podocytes have receptors for erythropoiesis stimulating proteins and illustrates how they may protect podocytes from apoptotic signaling in vitro and in vivo.
99. Eto N, Wada T, Inagi R, et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72:455-463.
100. Tsui CC, Shankland SJ, Pierchala BA. Glial cell line-derived neurotrophic factor and its receptor Ret is a novel ligand-receptor complex critical for survival response during podocyte injury. J Am Soc Nephrol 2006; 17:1543-1552. This study shows that Ret is activated upon podocyte injury in vitro and in vivo, where it may promote podocyte survival through an autocrine signaling loop.
101. Kanjanabuch T, Ma L-J, Chen J, et al. PPAR-γ agonist protects podocytes from injury. Kidney Int 2007; 71:1232-1239. This study identifies a role for the nuclear hormone receptor peroxidase proliferator-activated receptor-γ in protecting podocytes from pro-apoptotic signaling.
102. Xing C-Y, Saleem MA, Coward RJ, et al. Direct effects of dexamethasone on human podocytes. Kidney Int 2006; 70:1038-1045.
103. Wada T, Pippin JW, Marshall CB, et al. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol 2005; 16:2615-2625.